[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

What is the purpose of the study? (in Layman's terms, please describe the study)

This is a multicenter Phase 1b, open-label, dose -escalation and cohort -expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet), and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors.

Upstate Institutional Review Board (IRB) Number:

1978999

Study/Protocol ID:

XL092-002

Study Phase:

Phase 1

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

Who is eligible?

Those with a solid tumor that is unresectable or metastatic and for which life -prolonging therapies do not exist or available therapies are intolerable or no longer effective.

What is involved if I participate?

  • How long is the study?
    5 years
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    Blood test, urine test, CT scans, Bone scans, office visit

Where will the study take place?

SUNY Upstate Medical University

Other Information:

Please contact the CRA for more information.

Who can I contact for more information?

Name: Jennifer Newman
Phone: 315-464-8230
Email: [email protected]

Return to Previous Page || Search Again

Top